Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […] Vertex plans to submit regulatory filings seeking approval for ...

Despite this setback, Vertex’s zimislecel program for T1D is progressing positively, with plans for global regulatory submissions by 2026. Additionally, Vertex’s non-opioid pain medication ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the ...

Zimislecel, Vertex’s islet cell therapy, remains on track for Phase 3 completion in 2025, with regulatory submissions expected in 2026. China’s new tariffs just reignited the same market ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.